Polyarteritis nodosa when applying the Chapel Hill nomenclature - A descriptive study on ten patients

Rheumatology

Volumn 45, Issue 10, 2006, Pages 1276-1281

  Selga, D ^a   Mohammad, A ^a   Sturfelt, G ^a   Segelmark, M ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Incidence; Outcome; PAN; Polyarteritis nodosa; Relapses; Vasculitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; ANGIOGRAPHY; ARTERITIS; ARTICLE; BIOPSY TECHNIQUE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONSENSUS DEVELOPMENT; DESCRIPTIVE RESEARCH; DISEASE COURSE; DISEASE SEVERITY; ELECTROMYOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDIDYMIS BIOPSY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; MALE; MEDICAL ASSESSMENT; MENTAL DISEASE; MICROSCOPIC POLYANGIITIS; MUSCLE BIOPSY; NEUROLOGIC DISEASE; NOMENCLATURE; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; RELAPSE; SKIN BIOPSY; SWEDEN; SYMPTOM; SYSTEMIC VASCULITIS; TESTIS BIOPSY;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR SYSTEM; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NERVOUS SYSTEM; POLYARTERITIS NODOSA; RECURRENCE; SWEDEN; TERMINOLOGY; TERMINOLOGY AS TOPIC; TIME FACTORS; VASCULITIS;

EID: 33749636518     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel091     Document Type: Article

References (26)

1. Kussmaul A, Maier R. Uber eine bisher nicht beschreibene eigenthümliche Arterienerkankung (Periarteriitis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Deutsches Arch f klin Med 1866;1:84-517.
2. Wegener F. Uber eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystem und der Nieren. Beitr Pathol Anat 1939:36-38.
3. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. Q J Med 1948;17:175-205.
4. Zeek PM. Periarteritis nodosa: A critical review. Am J Clin Pathol 1952;22:777-90.
5. Lightfoot RW Jr, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-93.
6. Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 1970;19:410-1.
7. van der Woude FJ. Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet 1985;2:48.
8. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides: The proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
9. Guillevin L, Durand-Gasselin B, Cevallos R et al. Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-30.
10. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. Q J Med 2005; 98:97-111.
11. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52.
12. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32.
13. Kirkland GS, Savige J, Wilson D, Heale W, Sinclair RA, Hope RN. Classical polyarteritis nodosa and microscopic polyarteritis with medium vessel involvement - a comparison of the clinical and laboratory features. Clin Nephrol 1997;47:176-80.
14. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Qjm 1994;87:671-8.
15. Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 1996;75:17-28.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63.
18. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985;106:522-6.
19. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
20. Westman KW, Selga D, Isberg PE, Bladstrom A, Olsson H. High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2003;14:2926-33.
21. Fortin PR, Larson MG, Watters AK, Yeadon CA, Choquette D, Esdaile JM. Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group - a review of 45 cases. J Rheumatol 1995;22:78-84.
22. Agard C, Mouthon L, Mahr A, Guillevin L. Microscopic polyangiitis and polyarteritis nodosa: How and when do they start? Arthritis Rheum 2003;49:709-15.
23. Guillevin L, Lhote F, Cohen P et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine 1995;74:238-53.
24. Guillevin L, Le Thi Huong D, Godeau P, Jais P, Wechsler B. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: A study in 165 patients. Br J Rheumatol 1988;27:258-64.
25. Gayraud M, Guillevin L, le Toumelin P et al. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666-75.
26. Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DG. Geoepidemiology of systemic vasculitis: Comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001;60:170-2.